BPT-323

N/A

Report date: 2023/12/11 17:15:57

Base Information

Drug NameBPT-323
Drug Alias NameBPT-323
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTumor necrosis factor α inhibitorsInterleukin-2 receptor agonists
TargetsTumor necrosis factor αInterleukin-2 receptor
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBright Peak Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBright Peak Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A